drugset / Trial / NCT02283905

Amphotericin-B and Voriconazole for Pulmonary Blastomycosis

NCT02283905 ↗

Phase 4 Terminated 2 enrolled University of Manitoba Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

All patients with pulmonary blastomycosis requiring mechanical ventilation will have their blood concentrations measured for the antifungal drugs, amphotericin-B and voriconazole; as well as an analysis of the susceptibility of their infecting species of blastomyces. This information will then be analyzed relative to their rate of clinical recovery from this serious fungal infection.

Timeline

Start
2015-06
Primary completion
2020-09-25
Completion
2020-09-25

Outcome

Outcome not reported

Stopped (Enrollment): “Poor enrollment numbers of patients”

Drugs

EvaluationDrugModalityDoseRoute
Subject Amphotericin B Unknown 1 mg/kg —
Subject Voriconazole Small molecule 4 mg/kg Intravenous
Subject Voriconazole Small molecule 200 mg Intravenous
Subject Voriconazole Small molecule 400 mg Intravenous

Indications